epilepsy – Penn Bioengineering Blog

BE’s award-winning team, Epilog, at the 2024 Senior Design Awards.

How do you make robotics kits affordable for children in low-income countries? Speed up the manufacturing of organs-on-a-chip? Lower the environmental impact of condiments in restaurants?

If you’re a senior at Penn Engineering, the answer is to team up with your peers in the Senior Design Project Competition, which every year draws interdisciplinary groups from across the School’s six majors to solve real-world problems. Championed by the late Walter Korn (EE’57, GEE’68), a past president of the Engineering Alumni Society (EAS), Senior Design also invites alumni back to campus to evaluate the seniors’ year-long capstone projects.

Since the program started nearly two decades ago, hundreds of alumni have shared centuries’ worth of their collective experience with soon-to-be-minted graduates in the form of constructive feedback. “Senior Design is really one of the best days at Penn Engineering,” says Bradley Richards (C’92, LPS’17), Director of Alumni Relations, who manages the program. “Faculty advisors work with students all year long to bring out the best in each group’s efforts, and the results speak for themselves.”

This year, three student teams from each of Penn Engineering’s six departments — Bioengineering (BE), Chemical and Biomolecular Engineering (CBE), Computer and Information Science (CIS), Electrical and Systems Engineering (ESE), Materials Science and Engineering (MSE), and Mechanical Engineering and Applied Mechanics (MEAM) — presented their work to more than 60 alumni in person and online.

Judges’ Choice Award

The Judges’ Choice Award, which recognizes overall excellence, went to ESE’s VivoDisk, which developed a novel machine to manufacture organs-on-a-chip for Vivodyne, a startup launched by Dan Huh, Associate Professor in BE.

As one of the team members, Akash Chauhan (ENG’24), learned while interning for Vivodyne, assembling the stacks of organs-on-a-chip, which are collections of plastic plates containing cells that simulate organs for preclinical drug testing, is extremely finicky and time consuming.

By developing a machine that could automatically align the plates with high precision using computer vision and AI, the team reduced the disks’ manufacturing time and expense, leading Vivodyne to adopt the device for commercial use, accelerating the process of drug discovery. VivoDisk’s team members included Chauhan; Angela Rodriguez (ENG’24), Aliris Tang (ENG’24, W’24), Dagny Lott (ENG’24), Simone Kwee (ENG’24) and Vraj Satashia (ENG’24, GEN’25) and was advised by Sid Deliwala, Alfred Moore Senior Fellow and Director of Lab Programs in ESE, and Jan Van der Spiegel, Professor in ESE.

Technology and Innovation Award

One of the greatest challenges for children with epilepsy is status epilepticus, an abnormal type of long-lasting seizure that is hard to distinguish from typical seizures and that has a mortality rate of 30%. There is currently no way to perform a test for status epilepticus at home, meaning that children suspected of having the condition must be rushed to the hospital for an electroencephalogram.

Epilog, a team from BE, developed a novel, wearable headset that analyzes brainwaves to accurately determine whether or not a child suffering a seizure is actually suffering from status epilepticus. The team, composed of Rohan Chhaya (ENG’24, GEN’24), Carly Flynn (ENG’24), Elena Grajales (ENG’24), Priya Shah (ENG’24, GEN’25) and Doris Xu (ENG’24) and advised by Erin Berlew, Research Scientist in the Department of Orthopaedic Surgery and Lecturer in BE, carefully validated the device’s accuracy.

The judges recognized Epilog’s technological expertise, which ran the gamut from software to hardware, including a custom app to work with the device and carefully considered features like electrodes whose position can be adjusted to accommodate a child’s growth over time.

Read the full story in Penn Engineering Today.

July 29, 2024July 24, 2024

2024 CAREER Award Recipient: Flavia Vitale

by Melissa Pappas

Neurological disorders such as epilepsy, Alzheimers, Parkinson’s and certain forms of dementia are the leading cause of disability and second-leading cause of disease worldwide. These disorders disproportionately affect low-resourced communities due to lack of access to specialized healthcare, and many of these complex diseases lack curative solutions. The need to address neurological disorders is high, yet current diagnostics and treatments are not effective for preventative or personalized care and are not accessible or affordable enough to meet the needs of more than 3 billion people living with neurological disorders.

Flavia Vitale, Associate Professor in Bioengineering in Penn Engineering and in Neurology in Penn Medicine, works to meet this need, developing accessible and affordable solutions for the diagnosis, treatment and rehabilitation of people with neurological disorders.

“I started my research career in biomedical engineering hoping to one day help humanity,” says Vitale, who is also a 2024 recipient of a National Science Foundation (NSF) CAREER Award for her work. “But it wasn’t until I gained a more diverse skill set during my doctoral and postdoctoral research across chemical engineering and materials science that I was able to do that in a real way.”

Vitale’s multidisciplinary skills are what allow her to develop devices that help people living with brain disorders. The CAREER Award is now helping her further apply those skills and actualize some of her first long-term research projects at Penn.

“This CAREER Award will support my lab’s current research in leveraging innovation in materials and fabrication approaches to develop devices that are able to interface with and control different chemical and electrical signals inside the brain,” she says.

Focused primarily on understanding the brain activity involved in epilepsy-induced seizures, Vitale aims to design and develop brain-interface devices to pinpoint and suppress uncontrolled brain activity to prevent seizures from happening. Her work will lead to revolutionary health care for the 30% of epilepsy patients whose conditions are drug resistant. Currently those patients either wait out the uncontrolled brain activity and oftentimes life-threatening convulsions, or hope to be eligible for invasive surgeries to remove the part of the brain where seizures originate or to implant the seizure-controlling devices that are currently available.

Read the full story in Penn Engineering Today.

April 23, 2024April 23, 2024

2024 Penn Bioengineering Senior Design Projects Advance to Interdepartmental Competition

On April 17, 2024, the Department of Bioengineering held its annual Bioengineering (BE) Senior Design Presentations in the Singh Center for Nanotechnology, followed by a Design Expo in the George H. Stephenson Foundation Educational Laboratory & Bio-MakerSpace.

A panel of expert and alumni judges chose 3 teams to advance to the School-wide, interdepartmental competition, to be held on May 3, 2024.

Team ADONA: Jude Barakat, Allison Elliott, Daniel Ghaderi, Aditi Ghalsasi, Taehwan Kim

ADONA (A Device for the Assisted Detection of Neonatal Asphyxia)

Hypoxic-ischemic encephalopathy (HIE) is a condition that arises from inadequate oxygen delivery or blood flow to the brain around the time of birth, resulting in long-term neurological damage. This birth complication is responsible for up to 23% of neonatal deaths worldwide. While effective treatments exist, current diagnostic methods require specialized neurologists to analyze an infant’s electroencephalography (EEG) signal, requiring significant time and labor. In areas where such resources and specialized training are even scarcer, the challenges are even more pronounced, leading to delayed or lack of treatment, and poorer patient outcomes. The Assisted Detection of Neonatal Asphyxia (ADONA) device is a non-invasive screening tool that streamlines the detection of HIE. ADONA is an EEG helmet that collects, wirelessly transmits, and automatically classifies EEG data using a proprietary machine learning algorithm in under two minutes. Our device is low-cost, automated, user-friendly, and maintains the accuracy and reliability of a trained neurologist. Our classification algorithm was trained using 1100 hours of annotated clinical data and achieved >85% specificity and >90% sensitivity on an independent 200 hour dataset. Our device is now produced in Agilus 30, a flexible and tear resistant material, that reduces form factor and ensures regulatory compliance. For our final prototype, we hope to improve electrode contact and integrate software with clinical requirements. Our hope is that ADONA will turn the promise of a safer birth into a reality, ensuring instant peace of mind and equitable access to healthcare, for every child and their families.

Epilog

To address the critical need for effective, at-home seizure monitoring in pediatric neurology, particularly for Status Epilepticus (SE), our team developed Epilog: a rapid-application electroencephalography (EEG) headband. SE is a medical emergency characterized by prolonged or successive seizures and often presents with symptoms too subtle to notice or easily misinterpreted as post-convulsive fatigue. This leads to delayed treatment and increased risks of neurological damage and high mortality. Current seizure detection technologies are primarily based on motion or full-head EEG, rendering them ineffective at detecting SE and impractical for at-home use in emergency scenarios, respectively. Our device is designed to be applied rapidly during the comedown of a convulsive seizure, collect EEG data, and feed it into our custom machine learning algorithm. The algorithm processes this data in real-time and alerts caregivers if the child remains in SE, thereby facilitating immediate medical decision-making. Currently, Epilog maintains a specificity of 0.88 and sensitivity of 0.95, delivering decisions within 15 seconds post-seizure. We have demonstrated clean EEG signal acquisition from eight standard electrode placements and bluetooth data transmission from eight channels with minimal delay. Our headband incorporates all necessary electrodes and adjustable positioning of the electrodes for different head sizes. Our unique gel case facilitates rapid electrode gelation in less than 10 seconds. Our most immediate goals are validating our fully integrated device and improving features that allow for robust, long-term use of Epilog. Epilog promises not just data, but peace of mind, and empowering caregivers to make informed life-saving decisions.

NG-LOOP

Nasogastric (NG) tube dislodgement occurs when the feeding tube tip becomes significantly displaced from its intended position in the stomach, causing fatal consequences such as aspiration pneumonia. Compared to the 50% dislodgement rate in the general patient population, infant patients are particularly affected ( >60%) due to their miniature anatomy and tendency to unknowingly tug on uncomfortable tubes. Our solution, the Nasogastric Lightweight Observation and Oversight Product (NG-LOOP) provides comprehensive protection from NG tube dislodgement. Physical stabilization is combined with sensor feedback to detect and manage downstream complications of tube dislodgement. The lightweight external bridle, printed with biocompatible Accura 25 and coated with hydrocolloid dressing for comfort and grip, can prevent dislodgement 100% of the time given a tonic force of 200g. The sensor feedback system uses a DRV5055 linear hall effect sensor with a preset difference threshold, coupled with an SMS alert and smart plug inactivation of the feeding pump. A sensitivity of 90% and specificity of 100% in dislodgement detection was achieved under various conditions, with all feedback mechanisms being initiated in response to 100% of threshold triggers. Future steps involve integration with hospital-grade feeding pumps, improving the user interface, and incorporating more sizes for diverse age inclusivity.

Photos courtesy of Afraah Shamim, Coordinator of Educational Laboratories in the Penn BE Labs. View more photos on the Penn BE Labs Instagram.

Senior Design (BE 4950 & 4960) is a two-semester capstone course taught by David Meaney, Solomon R. Pollack Professor in Bioengineering and Senior Associate Dean of Penn Engineering, Erin Berlew, Research Scientist in the Department of Orthopaedic Surgery and Lecturer in Bioengineering, and Dayo Adewole, Postdoctoral Fellow of Otorhinolaryngology (Head and Neck Surgery) in the Perelman School of Medicine. Read more stories featuring Senior Design in the BE Blog.

January 27, 2024January 25, 2024

Bioengineers on the Brink of Breaching Blood-brain Barrier

by Nathi Magubane

From left: Emily Han, Rohan Palanki, Jacqueline Li, Michael Mitchell, Dongyoon Kim, and Marshall Padilla of Penn Engineering.

Imagine the brain as an air traffic control tower, overseeing the crucial and complex operations of the body’s ‘airport.’ This tower, essential for coordinating the ceaseless flow of neurological signals, is guarded by a formidable layer that functions like the airport’s security team, diligently screening everything and everyone, ensuring no unwanted intruders disrupt the vital workings inside.

However, this security, while vital, comes with a significant drawback: sometimes, a ‘mechanic’—in the form of critical medication needed for treating neurological disorders—is needed inside the control tower to fix arising issues. But if the security is too stringent, denying even these essential agents entry, the very operations they’re meant to protect could be jeopardized.

Now, researchers led by Michael Mitchell of the University of Pennsylvania are broaching this long-standing boundary in biology, known as the blood-brain barrier, by developing a method akin to providing this mechanic with a special keycard to bypass security. Their findings, published in the journal Nano Letters, present a model that uses lipid nanoparticles (LNPs) to deliver mRNA, offering new hope for treating conditions like Alzheimer’s disease and seizures—not unlike fixing the control tower’s glitches without compromising its security.

“Our model performed better at crossing the blood-brain barrier than others and helped us identify organ-specific particles that we later validated in future models,” says Mitchell, associate professor of bioengineering at Penn’s School of Engineering and Applied Science, and senior author on the study. “It’s an exciting proof of concept that will no doubt inform novel approaches to treating conditions like traumatic brain injury, stroke, and Alzheimer’s.”

Read the full story in Penn Today.

May 12, 2023May 16, 2023

Penn Medicine and Independence Blue Cross Eliminate Preapprovals for Imaging Tests

Brian Litt, Professor in Bioengineering in Penn Engineering and in Neurology in the Perelman School of Medicine, spoke to Neurology Today about the advances in technology for detecting and forecasting seizures.

The Litt Lab for Translational Neuroengineering translates neuroengineering research directly into patient care, focusing on epilepsy and a variety of research initiatives and clinical applications.

“Dr. Litt’s group is working with one of a number of startups developing ‘dry’ electrode headsets for home EEG monitoring. ‘They are still experimental, but they’re getting better, and I’m really optimistic about the possibilities there.'”

Read “How Detecting, Identifying and Forecasting Seizures Has Evolved” in Neurology Today.

Read more stories featuring Litt in the BE Blog.

April 5, 2023April 4, 2023

Novel Tools for the Treatment and Diagnosis of Epilepsy

by Nathi Magubane

A neurologist examines an encephalogram of a patient’s brain. — Throughout his career, Brian Litt has fabricated tools that support international collaboration, produced findings that have led to significant breakthroughs, and mentored the next generation of researchers tackling neurological disorders. (Image: iStock Photo/Alona Siniehina)

When Brian Litt of the Perelman School of Medicine and School of Engineering and Applied Science began treating patients as a neurologist, he found that the therapies and treatments for epilepsy were mostly reliant on traditional pharmacological interventions, which had limited success in changing the course of the disease.

People with epilepsy are often prescribed anti-seizure medications, and, while they are effective for many, about 30% of patients still continue to experience seizures. Litt sought new ways to offer patients better treatment options by investigating a class of devices that electronically stimulate cells in the brain to modulate activity known as neurostimulation devices.

Litt’s research on implantable neurostimulation devices has led to significant breakthroughs in the technology and has broadened scientists’ understanding of the brain. This work started not long after he came to Penn in 2002 with licensing algorithms to help drive a groundbreaking device by NeuroPace, the first closed-loop, responsive neurostimulator to treat epilepsy.

Building on this work, Litt noted in 2011 how the implantable neurostimulation devices being used at the time had rigid wires that didn’t conform to the brain’s surface, and he received support from CURE Epilepsy to accelerate the development of newer, flexible wires to monitor and stimulate the brain.

“CURE is one of the epilepsy community’s most influential funding organizations,” Litt says. “Their support for my lab has been incredibly helpful in enabling the cutting-edge research that we hope will change epilepsy care for our patients.”

Read the full story in Penn Today.

Brian Litt is a Professor in Bioengineering and Neurology.

Flavia Vitale is an Assistant Professor in Neurology with a secondary appointment in Bioengineering.

Jonathan Viventi is an Assistant Professor in Biomedical Engineering at Duke University.

December 15, 2017December 19, 2017

Week in BioE (December 15, 2017)

A New Model of the Small Intestine

Diseases of the small intestine, including Crohn’s disease and microbial infections, impose a huge burden on health. However, finding treatments for these diseases is challenged by the lack of optimal models for studying disease. Animal models are only so close to human disease states, and laboratory models using cell lines do not completely mimic the environment inside the gut.

However, these limitations might be overcome soon thanks to the research of scientists at Tufts University. In an article recently published in PLOS ONE, a team led by David L. Kaplan, Ph.D., of the Tufts Department of Biomedical Engineering, describes how they used donor stem cells and a compartmentalized biomimetic scaffold to model and generate small intestine cells that could differentiate into the broad variety of cell types common to that organ.

The study team tested the response of its cell model to E. coli, a common pathogen. At the genetic level, the model matched the reaction of the human small intestine when exposed to this bacterium. The success of the model could translate into its use in the near future to better understand the digestive system’s response to infection, as well as to test individualized treatments for inflammatory bowel diseases such as Crohn’s.

Saving Battle-wounded Eyes

The increase in combat survival rates has led to a higher incidence of veterans with permanent vision loss due to catastrophic damage to the eye. Globe injuries will recover of some vision, if caught in time. However, combat care for eye injuries often occurs hundreds or thousands of miles away from emergency rooms with attending ophthalmologists. With this unavoidable delay in treatment, people with globe injuries suffer blindness and often enucleation.

However, battle medics might soon have something in their arsenals to prevent such blinding injuries immediately in the combat theater. As reported recently in Science Translational Medicine, engineers at the University of Southern California (USC) and ophthalmologists from USC’s Roski Eye Institute have collaborated in creating a new material for temporary sealing of globe injuries. The study authors, led by John J. Whalen, III, Ph.D., used a gel called poly(N-isopropylacrylamide) (PNIPAM), already under investigation for treating retinal injuries. PNIPAM is a thermoresponsive sealant, meaning it is a liquid at cooler temperature but an adhesive gel at warmer temperature. These interesting properties mean PNIPAM can be applied as a liquid and then solidifies quickly on the eye. The authors manipulated PNIPAM chemically to make it more stable at body temperature. As envisioned, the gel, when used with globe injuries, could be applied by medics and then removed with cold water just before the eye is treated.

The study team has tested the gel in rabbits, where it showed statistically significant improvement in wound sealing and no negative effects on the eyes or overall health of the rabbits. The authors believe the material will be ready for human testing in 2019.

Predicting Seizures in Epilepsy

Epilepsy is a central nervous system disorder characterized by seizure activity that can range in severity from mild to debilitating. Many patients with epilepsy experience adequate control of seizures with medications; however, about a third of epileptic patients have intractable cases requiring surgery or other invasive procedures.

In what could be a breakthrough in the treatment of refractive epilepsy, scientists from Australia in collaboration with IBM Research-Australia have used big data from epilepsy patients to develop a computer model that can predict when seizures will occur. So far, the technology predicts 69% of seizures in patients. While it’s still short of a range of accuracy making it feasible for use in patients outside of experimental settings, the acquisition of ever-increasing amounts of data will render the model more accurately.

The Art of Genetic Engineering

Among the techniques used in genetic engineering is protein folding, which is one of the naturally occurring processes that DNA undergoes as it takes on three dimensions. Among the major developments in genetic engineering was the discovery of the ability to fold DNA strands artificially, in a process called DNA origami.

Now, as suggested by the name “origami,” some people have begun using the process in quasi-artistic fashion. In an article recently published in Nature, bioengineers at CalTech led by Lulu Qian, Ph.D., assistant professor of bioengineering, showed they were able to produce a variety of shapes and designs using DNA origami, including a nanoscale replica of Leonardo da Vinci’s Mona Lisa.

DNA now also has another unique artistic application — tattoos, although people’s opinions of whether tattooing constitutes art might vary. Edith Mathiowitz, Ph.D., of Brown University’s Center for Biomedical Engineering, is among the patenters of Everence, a technology that takes DNA provided by a customer and incorporates it into tattoo ink. Potential tattooees can now have the DNA of loved ones incorporated into their bodies permanently, if they should so wish.

People and Places

The University of Washington has launched its new Institute for Nano-engineered Systems, cutting the ribbon on the building on December 4. The center will house facilities dedicated to scalable nanomanufacturing and integrated photonics, among others. Meanwhile, at the University of Chicago, Rama Ranganathan, M.D., Ph.D., a professor in the Department of Biochemistry and Molecular Biology and the Institute for Molecular Engineering, will lead that college’s new Center for Physics of Evolving Systems. Congratulations!

Tag: epilepsy

Innovation in Action: Penn Engineering’s 2024 Senior Design Project Competition